TMCnet News

Bioserv Corporation Appoints Dr. Jay Schrier, Ph.D., as a New Member to Its Executive Team
[April 18, 2014]

Bioserv Corporation Appoints Dr. Jay Schrier, Ph.D., as a New Member to Its Executive Team


SAN DIEGO --(Business Wire)--

Bioserv Corporation, a contract manufacturer of injectable pharmaceuticals and medical devices, is pleased to announce the appointment of Jay Schrier, Ph.D., as Senior Vice President of Pharmaceutical Technologies.

Dr. Schrier brings over 25 years of broad analytical and pharmaceutical development experience to Bioserv and has helped create numerous cGMP-compliant analytical and pharmaceutical development departments within the pharmaceutical industry. Prior to joining Bioserv, he was Senior Director of Pharmaceutical Development at Pacira Pharmaceuticals.

Al Hansen, Chairman and CEO of Bioserv Corporation and Managing Partner at KESA Partners, commented: "We are excited to welcome someone with Dr. Schrier's outstanding qualifications and leadership skills to our growing exective team at Bioserv. His development expertise will result in significant value creation for our manufacturing clients. Dr. Schrier will provide expertise to our clients to enable them to manufacture their products to high quality standards but in a cost-effective manner."



About new appointment Jay Schrier, Ph.D.

Dr. Jay Schrier, Senior Vice President of Pharmaceutical Technologies, comes to Bioserv with more than 25 years of broad experience in the development of innovative drug products. Dr. Schrier was a significant contributor to the development of Recombinate™ (Antihemophilic Factor (recombinant)), BeneFIX® (Coagulation Factor IX (recombinant)), INFUSE® Bone Graft (rhBMP-2/absorbable collagen sponge), DepoDur® (liposomal morphine) and Exparel® (liposomal bupivacaine). He has created cGMP-compliant analytical and pharmaceutical development departments, and managed up to 30 professionals. He was Manager of the Pharmaceutical Technology Department at Genetics Institute (now part of Pfizer), and held positions as Senior Director of Biopharmaceutical Product Development at Magellan (News - Alert) Labs (now part of Catalent), Senior Director of Analytical Research and Development at SkyePharma, and Senior Director of Pharmaceutical Development at Pacira Pharmaceuticals.


Dr. Schrier holds an MS in Pharmacognosy and Natural Products Chemistry from Ohio State University and a Ph.D. in Pharmaceutical Sciences from the University of Kentucky.


[ Back To TMCnet.com's Homepage ]